echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JCO: H1-antihistamines reduce the risk of hepatocellular carcinoma in patients with HBV, HCV or HBV-HCV co-infection

    JCO: H1-antihistamines reduce the risk of hepatocellular carcinoma in patients with HBV, HCV or HBV-HCV co-infection

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Histamine is a biologically active substance that enhances the body's inflammatory and immune responses and acts as a neurotransmitter [1,2]
    .


    Antihistamines (AHs) are drugs that antagonize these effects by blocking or inhibiting receptors (H receptors) [3]


    immune infection

    The study included patients with HBV, HCV or HBV-HCV co-infection from the Taiwan Resident Health Insurance Research Database who were examined from January 1, 2006 to December 31, 2015, using the Kaplan-Meier method and Cox ratio simultaneously.
    Risk regression assessed the association between AH and HCC risk
    .

    Results A total of 521,071 patients with HBV infection, 169,159 patients with HCV infection, and 39,016 patients with HBV-HCV co-infection were included in this study
    .


    Compared with patients without AHs, patients with HBV, HCV or co-infection who used AHs had a significantly lower risk of HCC, with adjusted hazard ratios of 0.


    Figure 1.
    Cumulative incidence of HCC correlates with cDDD in AH

    (A) HBV cohort, (B) cDDD group in HBV cohort, (C) HCV cohort, (D) cDDD group in HCV cohort, (E) HBV-HCV co-infection cohort, and (F) HBV-HCV co-infection The cDDD group in the infected cohort
    .




    references

    1.


    Branco ACCC, Yoshikawa FSY, Pietrobon AJ, et al.
    Role of Histamine in Modulating the Immune Response and Inflammation.


    2.


    3.


    4.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.